Compare CDW Corp. (CDW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CDW Corp. vs TG Therapeutics Inc — how do they compare? CDW Corp. trades at $136.9 (market cap $16.92B), while TG Therapeutics Inc trades at $49.59 (market cap $7.64B). The key difference: CDW Corp. is far larger — about 2.2× TG Therapeutics Inc's market cap, and CDW Corp. pays a 1.86% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CDW | TGTX | |
|---|---|---|
Market Cap | $16.92B | $7.64B |
Sector | Technology | Health |
52-Week High | $170.77 | $59.06 |
52-Week Low | $99.30 | $26.94 |
Enterprise Value | $22.52B | $7.84B |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CDW trades at $135.79, down 0.47% on the day, with a bearish technical signal. The stock shows strong profitability with a 44.01% ROE and trades at a P/E of 16.27. Recent Q2 2026 earnings beat expectations with EPS of $2.91, driven by 10% revenue growth, though margin pressures were noted. Analyst consensus is bullish with a $148.67 price target. The company maintains a solid balance sheet with a debt-to-asset ratio of 39.8% as of 2024.
The outlook for CDW is positive due to AI and infrastructure demand, but margin compression and a CFO transition in 2027 pose risks. Upside potential exists if the company meets Q3 2026 EPS expectations of $2.91 and sustains revenue growth. Key risks include competitive pressures and macroeconomic volatility affecting IT spending.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
